Covid-19 vaccine candidate which would be administered via an arm patch, the latest to look at alternative methods of giving injections.
Unlike conventional vaccines that stimulate antibody production, the new PepGNP-Covid19 vaccine candidate focuses on T-cells, which are responsible for cellular immunity, to eliminate cells infected by the virus and prevent it from replicating.
British company Emergex Vaccines Holding Ltd developed the potential vaccine, while Unisanté medical research centre in Lausanne in collaboration with the city's CHUV hospital will run the trial, which started on Jan.
10. Professor Blaise Genton, head of the study, said this cellular immunity generates so-called "memory cells", which could make the vaccine more durable and could be better than others at protecting against potential variants of the virus.